In Vitro & In Vivo Diagnostic Substances Companies
FilingsAtlas covers 15 publicly traded US companies in the In Vitro & In Vivo Diagnostic Substances industry (SEC SIC code 2835). Together they are worth about $57.04B in market value; the largest are Idexx Laboratories (IDXX), Lantheus (LNTH), Neogen (NEOG). By revenue, the biggest is Idexx Laboratories with $4.30B in fiscal 2025. 2 of the 15 companies with a reported fiscal year were profitable.
| # | Company | Ticker | Market Cap | Revenue (latest FY) | Net Income | Revenue YoY | P/E |
|---|---|---|---|---|---|---|---|
| 1 | Idexx Laboratories Inc | IDXX | $41.27B | $4.30B FY2025 | $1.06B | +10.4% | 39.8 |
| 2 | Lantheus Holdings, Inc. | LNTH | $6.75B | $1.54B FY2025 | $233.6M | +0.5% | 29.3 |
| 3 | Neogen Corp | NEOG | $2.56B | $870.4M FY2026 | -$7.9M | -2.7% | — |
| 4 | Celldex Therapeutics, Inc. | CLDX | $2.20B | $1.5M FY2025 | -$258.8M | -78.0% | — |
| 5 | Intellia Therapeutics, Inc. | NTLA | $1.59B | $67.7M FY2025 | -$412.7M | +16.9% | — |
| 6 | QuidelOrtho Corp | QDEL | $963.0M | $2.73B FY2025 | -$1.13B | -1.9% | — |
| 7 | Achieve Life Sciences, Inc. | ACHV | $654.6M | $0 FY2025 | -$54.6M | — | — |
| 8 | Alpha Teknova, Inc. | TKNO | $440.9M | $40.5M FY2025 | -$17.3M | +7.3% | — |
| 9 | Myriad Genetics Inc | MYGN | $386.8M | $824.5M FY2025 | -$365.9M | -1.6% | — |
| 10 | Insight Molecular Diagnostics Inc. | IMDX | $109.9M | $4.1M FY2025 | -$50.2M | +115.6% | — |
| 11 | Immucell Corp | ICCC | $99.2M | $27.6M FY2025 | -$1.0M | +4.3% | — |
| 12 | Biomerica Inc | BMRA | $5.4M | $4.5M FY2026 | -$3.8M | -16.2% | — |
| 13 | Cardio Diagnostics Holdings, Inc. | CDIO | $5.2M | $14,825 FY2025 | -$6.5M | -57.5% | — |
| 14 | TNF Pharmaceuticals, Inc. | TNFA | $4.5M | — FY2025 | -$11.6M | — | — |
| 15 | Volitionrx LTD | VNRX | $1.6M | $1.7M FY2025 | -$23.4M | +40.0% | — |
Market cap and P/E use the latest closing price; revenue and net income are from each company's most recent annual report (10-K) filed with the SEC. Click a company for its full financial statements.